Table 2.
Expression of the new markers in ALL cells relative to their expression in bone marrow CD19+CD10+ cells from healthy individuals as determined by flow cytometry
| Marker | No. of ALL cases studied | No. of cases with overexpression (%)* | No. of cases with underexpression (%)† |
|---|---|---|---|
| CD44 | 86 | 46 (53.5) | 24 (27.9) |
| BCL2 | 77 | 59 (76.6) | |
| HSPB1 | 93 | 59 (63.4) | |
| CD73 | 77 | 42 (54.5) | |
| CD24 | 139 | 16 (11.5) | 55 (39.6) |
| CD123 | 142 | 72 (50.7) | |
| CD72 | 45 | 22 (48.9) | |
| CD86 | 135 | 63 (46.7) | |
| CD200 | 95 | 41 (43.2) | |
| CD79b | 74 | 31 (41.9) | |
| CD164 | 75 | 31 (41.3) | |
| CD304 | 129 | 37 (28.7) | |
| CD97 | 81 | 22 (27.2) | |
| CD102 | 76 | 15 (19.7) | 2 (2.6) |
| CD99 | 77 | 17 (22.1) | |
| CD300A | 92 | 18 (19.6) | |
| CD130 | 71 | 12 (16.9) | |
| PBX1 | 64 | 4 (11.8) | |
| CTNNA1 | 44 | 4 (9.1) | |
| ITGB7 | 90 | 7 (7.8) | |
| CD69 | 33 | 2 (6.1) | |
| CD49f | 38 | 2 (5.3) | |
| EPOR | 45 | 2 (4.4) | |
| CD1C | 86 | 3 (3.5) | |
| CD120a | 35 | 1 (2.9) | |
| CD37 | 46 | 1 (2.2) | |
| CD62L | 34 | 0 | |
| CD132 | 33 | 0 | |
| CD83 | 33 | 0 | |
| IL13RA1 | 10 | 0 |
ALL indicates acute lymphoblastic leukemia; and MFI, mean fluorescence intensity.
*
Number of ALL cases that expressed the indicated marker at levels higher than the highest MFI value recorded among normal B-cell progenitors, and had an MFI higher than 10.
†
Number of ALL cases that expressed the indicated marker at levels lower than the lowest MFI measured in normal B-cell progenitors, excluding cases in which a marker had an MFI lower than 10 on normal B-cell progenitors.